Main VWF/ADAMTS13 features at presentation and at initial remission of the first TMA attack of the 6 relapsing patients during the 18-month follow-up
| Patient no. . | VWFAg, IU/dL . | ADAMTS13 Ag, ng/mL . | ADAMTS13 inhibitor titer . | Anti-ADAMTS13 IgG titer, 1/dilution . | ADAMTS13 activity, %; inhibitor in remission . |
|---|---|---|---|---|---|
| 6 | 140 | 450 | +++ | 200 | < 5; ++ |
| 13 | 180 | 145 | +++ | 800 | < 5; ++ |
| 14 | 245 | 75 | + | 400 | < 5; + |
| 16 | 140 | 1010 | +++ | 800 | < 5; ++ |
| 21 | 70 | 300 | +++ | 1600 | 15; − |
| 27 | 140 | 160 | − | 200 | < 5; − |
| Patient no. . | VWFAg, IU/dL . | ADAMTS13 Ag, ng/mL . | ADAMTS13 inhibitor titer . | Anti-ADAMTS13 IgG titer, 1/dilution . | ADAMTS13 activity, %; inhibitor in remission . |
|---|---|---|---|---|---|
| 6 | 140 | 450 | +++ | 200 | < 5; ++ |
| 13 | 180 | 145 | +++ | 800 | < 5; ++ |
| 14 | 245 | 75 | + | 400 | < 5; + |
| 16 | 140 | 1010 | +++ | 800 | < 5; ++ |
| 21 | 70 | 300 | +++ | 1600 | 15; − |
| 27 | 140 | 160 | − | 200 | < 5; − |
Anti-ADAMTS13 IgM titer and anti-ADAMTS13 IgA titer equal 0 for all patients listed in this table.
+++ indicates high; ++, medium; +, low; −, negative.